Naslov
Reevaluation of HER2 using CISH method in patients with invasive breast cancer

Autori
Ramić, Snježana ; Perić Balja, Melita ; Knežević, Fabijan

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Book of Abstracts / - Osijek, 2008, 59-59

Skup
4. Hrvatski kongres patologa i sudskih medicinara

Mjesto i datum
Osijek, Hrvatska, 25.09.2008. - 28.09.2008

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
breast cancer ; HER2 ; chromogenic in situ hybridization

Sažetak
AIM OF STUDY. The human epidermal growth receptor 2 (HER2) has been routinely evaluated in patients with invasive breast cancer. Patients with positive HER2 score 3+ have HER2 overexpression/gene amplification, associated with worst prognosis and higher mortality rate although could benefit of Trastuzumab (Herceptin™), a monoclonal anti-HER2 therapy. However, equivocal HER2 score 2+ should be retested with FISH or CISH method to evaluate the rate of gene amplification. We presented results of chromogenic in situ hybridization (CISH) method, recently introduced in clinical practice. METHODS. HER2 status was evaluated using immnunohistochemical staining Hercep test by Dako. CISH is “in situ” hybridization technique alternative to FISH which uses permanent chromogen dyes for visualization of bonded DNA probe and detection of gene amplification rate on paraffin-embedded tissue (Zymed’s SPoT-Light® HER2 CISH Kit). Increased number of signal dots referring to gene amplification, present in more than 50% of tumor cells, considered positive when 6 to 10 single dots or mixture of multiple dots and small clusters were found per nucleus (low amplification) and more than 10 signal dots or large clusters or mixture of multiple dots and large clusters were found per nucleus (high amplification). RESULTS. In 1622 patients with invasive breast cancer 211 (13%) cases had HER2 score 3+ and 184 (11.3%) had HER2 score 2+. Reevaluating gene amplification rate with CISH method in 166 cases 29 (17.4%) had low and 21 (12.6%) had high gene amplification rate. CONCLUSION. CISH assay confirmed as a good, easy and low-cost diagnostic tool for retesting of equivocal HER2 2+ score. This sensitive method is more suitable for clinical use because it creates permanent tissue slides and permits pathologist to observe gene amplification and morphology of tumor cells in the same time.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Kongres s međunarodnim sudjelovanjem

POVEZANOST RADA